SCHEMBL23460109

SCHEMBL23460109

COC(=O)c1sc(-c2ccncc2)c2c1NCCO2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.37
HSD17B10 Q99714 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
RCE1 Q9Y256 2/20 0.37
HTT P42858 2/20 0.36
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
MAPK10 P53779 3/20 0.35
MAPK8 P45983 2/20 0.35
MAPK1 P28482 2/20 0.35
CYP46A1 Q9Y6A2 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
RET P07949 1/20 0.34
CDC7 O00311 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23485236 0.85 CDC7 (0.39) KDM4EHSD17B10ALDH1A1MAPK8ADORA3
SCHEMBL23459611 0.84 CDC7 (0.41) KDM4EMAPK8CDC7DBF4CCNE1
Lithium Ion SCHEMBL23459485 0.83 KDM4E (0.31) KDM4EMAPT
SCHEMBL23485570 0.77 MAPT (0.35) KDM4EHSD17B10ALDH1A1HPGDRET
SCHEMBL23459610 0.76 MAPT (0.34) HSD17B10RETMAPTKMT2A
SCHEMBL23459491 0.75 NEK1 (0.35) KDM4EHSD17B10ALDH1A1GAAHPGD
SCHEMBL29997650 0.75 NEK1 (0.35) KDM4EHSD17B10ALDH1A1GAAHPGD
SCHEMBL29997633 0.71 BAZ2B (0.39) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL23485549 0.69 GPR35 (0.32)
SCHEMBL23460395 0.69 BAZ2B (0.42) KDM4EALDH1A1HPGDHTTNCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230101747-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2023-03-30 US disclosed
EP-4069369-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-10-12 EP disclosed
WO-2021113492-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. (US) 2021-06-10 WO disclosed
WO-2021113492-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101747-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME PLK1, DCK, CSNK1A1 KDM4E 2909/4885HSD17B10 1417/4885ALDH1A1 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.